



## UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Minutes

Meeting Date: June 9, 2022

Location: Via conference call/Teams

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
Meeting called to order	G. Shutzberg	5:01 PM		
<b>A. Minutes from previous meetings</b>	G. Shutzberg	<b>Review of Minutes from March 10, 2022</b>	Minutes reviewed, approved	Yes
<b>A. Introduction - P&amp;T Committee Updates</b>	A. Volberg	Review of EQuIPP Pharmacy Quality Solutions: Presented additional program information as requested from last quarter's meeting of how Unitedhealthcare works in partnership with CMS to develop pharmacy quality measurements for programs such as STARS and HEDIS and the geographical coverage area.	Non voting item	N/A
	Comment:	Discussion held regarding the geographic coverage area and a request for additional information to be sent via email from internal regional account pharmacist of IN, Monica Blankenship.		
<b>B. Formulary Review - New Drugs</b>	C. Lichtinger	<b>Adbry</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	C. Lichtinger	<b>Cibinqo</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	C. Lichtinger	<b>Besremi</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	Comment:	Discussion held regarding the drug indication and continuation of therapy.		

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
<b>B. Formulary Review - New Drugs (cont.)</b>	C. Lichtinger	<b>Livtency</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	M. Reisman	<b>Purified Cortrophin Gel</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	M. Reisman	<b>Recorlev</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	M. Reisman	<b>Seglentis</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	M. Reisman	<b>Tarpeyo</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	M. Reisman	<b>Voxzogo</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	Comment:	Discussion held regarding the drug indication and time frame of therapy.		
<b>C. Formulary Review - PDL Modifications</b>	M. Reisman	<b>Confirm Review of PDL Modifications Grid</b>	Yes/No	Yes
		Recommendation: • <b>Fluocinonide 0.05% topical cream:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Fexofenadine 60 mg and 180 mg tablet:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
<b>C. Formulary Review - PDL Modifications (cont.)</b>	M. Reisman	Recommendation: • <b>Albuterol HFA 90 mcg/actuation inhalation aerosol:</b> Move two NDCs to preferred across all applicable lines of business. All generic albuterol HFA products will be preferred.	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Diclofenac 1% topical gel:</b> Brand and generic OTC and generic Rx product are remaining preferred, with the prior authorization requirement being removed across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Diclofenac 1.5% topical solution:</b> Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Tretinoin 0.025%, 0.05%, 0.1% topical cream:</b> Move to preferred open access for members under 18 years of age across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Norditropin 5 mg/1.5mL and 10 mg/1.5mL injection:</b> Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Breo Ellipta:</b> Move to preferred for NY EPP only	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Wixela Inhub:</b> Move to non-preferred with prior authorization for NY EPP only	Motion made, seconded, and carried to accept recommendation	11:0
<b>D. Formulary Review - New Drugs-Medical</b>	C. Lichtinger	<b>Confirm Review of New Drugs- Medical Grid</b>	Yes/No	Yes
		<b>Fyarro</b> Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		<b>Xipere</b> Recommendation: • Medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
D. Formulary Review - New Drugs-Medical (cont.)	C. Lichtinger	<b>Vyvgart</b>		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		<b>Tezspire</b>		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		<b>Apretude</b>		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		<b>Aduhelm</b>		
		Recommendation: • Medical benefit with prior authorization per individual state guidance	Motion made, seconded, and carried to accept recommendation	11:0
		<b>Enjamyo</b>		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		<b>Kimmtrak</b>		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
<b>Vabysmo</b>				
Recommendation: • Medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0		
<b>Leqvio</b>				
Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0		

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
<b>E. Formulary Review - Drugs Evaluated Per Grid</b>	M. Reisman	<b>Apply recommendations as outlined in grid</b>	Motion made, seconded, and carried to accept recommendation	11:0
<b>F. Clinical Guidelines</b>	M. Reisman	<b>Clinical Guideline Review</b>		
		<b>Apply New Pharmacy Guidelines</b>	Motion made, seconded, and carried to accept recommendation	11:0
		<b>Continue to Apply Pharmacy Guidelines Requiring Modifications</b>	Motion made, seconded, and carried to accept recommendation	11:0
		<b>Remove Pharmacy Guidelines Requiring Archival</b>	Motion made, seconded, and carried to accept recommendation	11:0
<b>G. Quality Monitoring</b>	L. Charlton/G. Shutzberg/ C. Lichtinger	<b>Confirm Review of Quality Data</b>	Yes/No	Yes
	L. Charlton	DUR Review		
	G. Shutzberg	COVID Dashboard		
	G. Shutzberg	Drug Recalls Q1 2022		
	C. Lichtinger	Top 25 Drugs by Spend and Volume – 1st Quarter 2022		
	C. Lichtinger	Top 10 Drugs Requested - Approvals and Denials – 1st Quarter 2022		
	C. Lichtinger	Grievances and Appeals Data – 1st Quarter 2022		
	C. Lichtinger	Inter-Rater Reliability (IRR) – 1st Quarter 2022 • Pharmacists		
<b>Adjournment</b>	G. Shutzberg		6:33 PM	
Comments:				

Respectfully Submitted to the Committee,

James P. Hancovsky, M.S.I.A., R.Ph.  
Chief Pharmacy Officer, UHC C&S